RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025

Stock Information for Lineage Cell Therapeutics, Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lineage Cell Therapeutics, Inc.

Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes
Lineage Cell Therapeutics to Present at September 2025 Investor Conferences
Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance(TM) (ANP1) for Hearing Loss
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.